Iatrogenic angioedema associated with ACEi, sitagliptin, and deficiency of 3 enzymes catabolizing bradykinin

European Annals of Allergy and Clinical Immunology

Volumn 46, Issue 3, 2014, Pages 119-122

  Beaudouin, E ^a   Defendi, F ^b,c   Picaud, J ^a   Drouet, C ^b,c   Ponard, D ^d   Moneret Vautrin, D A ^e  

^a Allergy Department   (France)

^b French Reference Centre of Kinin Mediated Angio Oedemas   (France)

^c UNIV GRENOBLE ALPES   (France)

^d Laboratoire d'Immunologie IBP   (France)

^e UNIVERSITÉ DE LORRAINE   (France)

Author keywords

Bradykinin; Enzyme deficiency; Iatrogenic angioedema

Indexed keywords

AMINOPEPTIDASE P; ARGININE CARBOXYPEPTIDASE; ATORVASTATIN; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLURBIPROFEN; GLIBENCLAMIDE; LISINOPRIL; METFORMIN; PREDNISOLONE; SITAGLIPTIN;

ADULT; ANGIONEUROTIC EDEMA; ARTICLE; CASE REPORT; DISEASE ASSOCIATION; DRUG WITHDRAWAL; ENZYME DEFICIENCY; HUMAN; IATROGENIC DISEASE; MALE; MEDICAL HISTORY; NON INSULIN DEPENDENT DIABETES MELLITUS;

BRADYKININ; ENZYME DEFICIENCY; IATROGENIC ANGIOEDEMA;

AMINO ACID METABOLISM, INBORN ERRORS; AMINOPEPTIDASES; ANGIOEDEMA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BRADYKININ; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOWN-REGULATION; DRUG INTERACTIONS; HUMANS; IATROGENIC DISEASE; LISINOPRIL; LYSINE CARBOXYPEPTIDASE; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; POLYPHARMACY; PYRAZINES; RISK FACTORS; TIME FACTORS; TRIAZOLES;

EID: 84903269768     PISSN: 17641489     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Hoover T, Lippmann M, Grouzmann E, Marceau F, Herscu P. Angiotensin converting enzyme inhibitor induced angio-oedema: a review of the pathophysiology and risk factors. Clin Exp Allergy. 2010;40:50-61.
2. Maurer M, Bader M, Bas M, Bossi F, Cicardi M, Cugno M et al. New topics in bradykinin research. Allergy. 2011;66:1397-1406.
3. Adam A, Cugno M, Molinaro G, Perez M, Lepage Y, Agostoni A. Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. Lancet. 2002;359:2088-9.
4. Adam A, Désormeaux A, Moreau M-E. [Physiopathology of the acute adverse effects of angiotensin-converting-enzyme inhibitors]. Bull Acad Natl Med. 2007;191:1433-43;disc 1443-4.
5. Drouet C, Désormeaux A, Robillard J, Ponard D, Bouillet L, Martin L et al. Metallopeptidase activities in hereditary angioedema: effect of androgen prophylaxis on plasma aminopeptidase P. J Allergy Clin Immunol. 2008;121:429-33.
6. Byrd JB, Touzin K, Sile S, Gainer JV, Yu C, Nadeau J et al. Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor-Associated Angioedema. Hypertension. 2008;51:141-7.
7. Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension. Sept2009;54:516-23.
8. Drouet C, Alibeu C, Ponard D, et al. A sensitive method to assay blood complement C1 Inhibitor activity. Clin Chim Acta. 1988;174:121-30.
9. Defendi F, Charignon D, Ghannam A, Baroso R, Csopaki F, Allegret-Cadet M, Ponard D, Favier B, Cichon S, Nicolie B, Fain O, Martin L, Drouet C. National Reference Centre for Angioedema CREAK. Enzymatic assays for the diagnosis of bradykinin-dependent angioedema. PLoS One. 2013;8:e70140.
10. Morimoto T, Gandhi TK, Fiskio JM, Seger AC, So JW, Cook EF et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract. 2004;10:499-509.
11. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens. 2004;17:103-11.
12. Agostoni A, Cicardi M, Cugno M, Zingale LC, Gioffré D, Nussberger J. Angioedema due to angiotensin-converting enzyme inhibitors. Immunopharmacology. 1999;44:21-5.
13. Chiu AG, Newkirk KA, Davidson BJ, Burningham AR, Krowiak EJ, Deeb ZE. Angiotensin-converting enzyme inhibitor-induced angioedema: a multicenter review and an algorithm for airway management. Ann Otol Rhinol Laryngol. 2001;110:834-40.
14. Grant NN, Deeb ZE, Chia SH. Clinical experience with angiotensin-converting enzyme inhibitor-induced angioedema. Otolaryngol Head Neck Surg. 2007;137:931-5.
15. Banerji A, Clark S, Blanda M, LoVecchio F, Snyder B, Camargo CA Jr. Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department. Ann Allergy Asthma Immunol. 2008;100:327-32.
16. Moreau ME, Dubreuil P, Molinaro G, Chagnon M, Müller-Esterl W, Lepage Y et al. Expression of metallopeptidases and kinin receptors in swine oropharyngeal tissues: effects of angiotensin I-converting enzyme inhibition and inflammation. J Pharmacol Exp Ther. 2005;315:1065-74.
17. Agostoni A, Cicardi M, Cugno M, Zingale LC, Gioffré D, Nussberger J. Angioedema due to angiotensin-converting enzyme inhibitors. Immunopharmacology. 1999;44:21-5.
18. Nussberger J, Cugno M, Cicardi M. Bradykinin-mediated angioedema. N Engl J Med. 2002;347:621-2.
19. Woodard-Grice AV, Lucisano AC, Byrd JB, Stone ER, Simmons WH, Brown NJ. Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema. Pharmacogenet Genomics. 2010;20:532-6.
20. Cilia La Corte AL, Carter AM, Rice GI, Duan QL, Rouleau GA, Adam A et al. A functional XPNPEP2 promoter haplotype leads to reduced plasma aminopeptidase P and increased risk of ACE inhibitor-induced angioedema. Human Mutation. 2011;32:1326-31.
21. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696-1705.
22. Grouzmann E, Buclin T. Is dipeptidylpeptidase IV the missing link in angiotensin-converting enzyme inhibitor--induced angioedema? Hypertension. 2008;51:45-7.
23. Lefebvre J, Murphey LJ, Hartert TV, Jiao Shan R, Simmons WH, Brown NJ. Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema. Hypertension. 2002;39:460-4.
24. Saisho Y, Itoh H. Dipeptidyl peptidase-4 inhibitors and angioedema: a class effect? Diabet Med. 2013;30:e149-50.